Institut d'Investigacions Biomèdiques August Pi i Sunyer-ko ikertzaileekin lankidetzan egindako argitalpenak (13)

2022

  1. Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository

    Arthritis Care and Research, Vol. 74, Núm. 2, pp. 324-335

2021

  1. Antiphospholipid antibody profile stability over time: Prospective results from the APS ACTION clinical database and repository

    Journal of Rheumatology, Vol. 48, Núm. 4, pp. 541-547

2020

  1. Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort

    Arthritis and Rheumatology, Vol. 72, Núm. 10, pp. 1734-1740

  2. Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index

    Arthritis and Rheumatology, Vol. 72, Núm. 4, pp. 658-666

2019

  1. Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository

    Journal of Thrombosis and Haemostasis, Vol. 17, Núm. 12, pp. 2069-2080

  2. Osteopontin and disease activity in patients with recent-onset systemic Lupus Erythematosus: Results from the SLICC Inception Cohort

    Journal of Rheumatology, Vol. 46, Núm. 5, pp. 492-500

  3. The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody–Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository

    Arthritis Care and Research, Vol. 71, Núm. 1, pp. 134-141

2017

  1. The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study

    Schizophrenia Research, Vol. 189, pp. 84-90

2016

  1. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies

    Seminars in Arthritis and Rheumatism, Vol. 45, Núm. 4, pp. 391-399

  2. Off-label use of rituximab for systemic lupus erythematosus in Europe

    Lupus Science and Medicine, Vol. 3, Núm. 1

2015

  1. Mood disorders in systemic lupus erythematosus: Results from an international inception cohort study

    Arthritis and Rheumatology, Vol. 67, Núm. 7, pp. 1837-1847

2013

  1. Belimumab en el lupus eritematoso sistémico: una guía para su uso en la práctica diaria

    Revista Clinica Espanola

2012

  1. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts

    Autoimmunity Reviews, Vol. 11, Núm. 5, pp. 357-364